Vietnam Investment Review on MSN24m
Innovent Biologics: Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian CancerSAN FRANCISCO and SUZHOU, China, March 23, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback